GlassScriptPhysician profile
Mohamed A Khalil
NPI 1124391198
$16,924.77
in general payments reported to CMS, 2019-2025
72 companies · $3,612 in 2025
The $3,612 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $1,196 · 2021: $1,688 · 2022: $2,677 · 2023: $2,940 · 2024: $3,378 · 2025: $3,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,926 · Education: $2.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,926.47 |
| Education | $2.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,588.40 | 2019-2025 | |
| Ucb, INC. | $1,443.61 | 2021-2025 | Fintepla, Rystiggo, Nayzilam |
| Abbvie INC. | $1,366.76 | 2021-2025 | |
| Sk Life Science, INC. | $889.31 | 2020-2025 | Xcopri |
| Lundbeck LLC | $675.01 | 2019-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $674.05 | 2021-2025 | Hyqvia, Gammagard |
| Grifols USA, LLC | $660.41 | 2019-2025 | Gamunex-C, Xembify |
| Pfizer INC. | $633.32 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $563.28 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $527.66 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $511.12 | 2021-2025 | |
| Allergan, INC. | $508.21 | 2019-2022 | |
| Argenx US, INC. | $502.49 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $407.03 | 2020-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $382.99 | 2019-2022 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $354.46 | 2019-2024 | Austedo Xr |
| Biogen, INC. | $330.14 | 2019-2025 | Spinraza, Vumerity, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $267.67 | 2022 | |
| Genentech USA, INC. | $260.05 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $249.02 | 2022-2023 | Nuplazid |
| Kerecis Limited | $222.39 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Biohaven Pharmaceuticals, INC. | $193.52 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $189.52 | 2025 | Purified Cortrophin Gel |
| W. L. Gore & Associates, INC. | $181.64 | 2024 | Gore Cardioform Septal Occluder |
| Mallinckrodt Hospital Products INC. | $172.35 | 2020-2025 | Acthar |
| Csl Behring | $169.02 | 2023-2025 | Hizentra |
| Tg Therapeutics, INC. | $166.64 | 2025 | |
| Lilly USA, LLC | $164.78 | 2019-2024 | Kisunla, Amyvid |
| Kyowa Kirin, INC. | $162.83 | 2019-2021 | |
| Amgen INC. | $158.09 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $150.13 | 2019-2022 | |
| Hospira, INC. | $131.48 | 2024-2025 | |
| Assertio Therapeutics, INC. | $122.69 | 2019-2020 | |
| Abbott Laboratories | $105.50 | 2024-2025 | Infinity |
| Janssen Pharmaceuticals, INC | $99.97 | 2019-2020 | |
| Boston Scientific Corporation | $95.68 | 2021-2023 | Vercise |
| Vertical Pharmaceuticals, LLC | $93.25 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $91.91 | 2021-2022 | |
| Octapharma USA, INC. | $85.47 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $85.00 | 2024-2025 | |
| Corium, LLC | $80.65 | 2023 | Adlarity |
| Springworks Therapeutics, INC. | $80.44 | 2024-2025 | Gomekli |
| Arbor Pharmaceuticals, INC. | $78.76 | 2019-2020 | |
| Avion Pharmaceuticals | $77.44 | 2022 | |
| Sumitomo Pharma America, INC. | $70.58 | 2024 | Aptiom |
| Mdd US Operations, LLC | $69.95 | 2019-2020 | |
| Acorda Therapeutics, INC | $55.11 | 2019-2020 | |
| Aucta Pharmaceuticals, INC. | $54.13 | 2024-2025 | Motpoly Xr |
| Emd Serono, INC. | $53.92 | 2022-2023 | Mavenclad |
| Azurity Pharmaceuticals, INC. | $49.81 | 2024-2025 | Horizant |
| Amneal Pharmaceuticals LLC | $45.03 | 2022-2025 | Crexont |
| Livanova USA, INC. | $44.60 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ipsen Biopharmaceuticals, INC | $42.70 | 2019-2024 | Dysport |
| Upsher-Smith Laboratories LLC | $41.71 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $41.64 | 2023-2024 | Rexulti |
| Ge Healthcare | $40.22 | 2019 | |
| Promius Pharma LLC | $38.31 | 2019 | |
| Banner Life Sciences, LLC | $33.22 | 2022 | |
| Amarin Pharma, INC. | $30.67 | 2019-2020 | |
| Tanabe Pharma America, INC. | $29.48 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $28.74 | 2019 | |
| Currax Pharmaceuticals LLC | $28.28 | 2021-2023 | Onzetra Xsail |
| Scilex Pharmaceuticals INC. | $28.18 | 2019-2020 | |
| Almatica Pharma LLC | $26.15 | 2021 | |
| Cycle Pharmaceuticals INC | $23.43 | 2025 | Tascenso Odt |
| Averitas Pharma INC. | $19.06 | 2025 | Qutenza |
| Zyla Life Sciences, INC. | $18.66 | 2019 | |
| Axsome Therapeutics, INC. | $16.78 | 2025 | Symbravo |
| Strongbridge US INC. | $14.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.